An Opened, Non-controlled, Multi-center Study of M118102 in Subjects with Asteatosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080223223

Enrollment

Registered

2016-05-31

Start date

2016-05-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asteatosis

Interventions

investigational material(s) Generic name etc : M118102 INN of investigational material : Heparinoid Therapeutic category code : 333 Anticoagulants Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Asteatosis Patients

Exclusion criteria

Exclusion criteria: (1) Patients with a history of any of the following: 1) Serious allergy (shock, anaphylactic symptoms) 2) Allergy to heparinoid 3) Cutaneous hypersensitivity to topical medicines (such as contact dermatitis) 4) Hemorrhagic blood disorder (hemophilia , thrombocytopenia , purpura ) (2) Patients with the following concurrent diseases: 1) Patients with any disorders that should not be enrolled in the sutdy such as; -severe cardiac disorders -severe hepatic disorders -severe pulmonary disorders -severe gastrointestinal disorders -severe blood disorders 2) Supervening skin disease on Asteatosis 3) Hemorrhagic blood disorder (hemophilia , thrombocytopenia , purpura ) (3) Pregnant women, women who may be pregnant, lactating women or women who wish to become pregnant or women who are unwilling to use a suitable method of contraception as directed by the principal investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
efficacy Therapeutic effect of maintaining	—

Secondary

Measure	Time frame
efficacy Changes over time in the severity scale of Asteatosis	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026